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To the Editor: A recently published report by Takemoto
et al.1 showed nice images of amyloid deposition in the
juxtaglomerular apparatus. Although the authors attributed
hyporeninemia to the amyloid deposition in the reported
case, other conditions of the case might have contributed to
hyporeninemia; hyporeninemic hypoaldosteronism can be
seen in several conditions, including advanced age, without
the amyloid deposition.2 In these conditions, the blood
volume is usually expanded rather than depleted, and
fludrocortisone should not be used.
Hypoaldosteronism induces salt-wasting in renal distal
tubules, which can cause hyperkalemia, but with normal
renal function it typically will not induce hyperkalemia.
Hyperkalemia is commonly seen in association with renal
insufficiency, which is frequently accompanied by the volume
expansion. Therefore, the reported patient, who had
hyperkalemia with an estimated glomerular filtration ratio
of B40 ml/min per 1.73 m2, is more likely to have had the
expanded volume at the time of diagnosis. With the volume
expansion, medication that facilitates the distal tubular
delivery of chloride, such as loop diuretics, would be
appropriate, and medication that facilitates the distal tubular
sodium reabsorption, such as fludrocortisone, could have
exacerbated the volume expansion.
In addition, during treatment by fludrocortisone, serum
sodium concentration should be monitored. Hyponatremia is
a feature of renal salt-wasting; the volume depletion
stimulates anti-diuretic hormone secretion. In severe hypo-
natremia, increasing serum sodium concentration faster than
8 mmol/l per day, should be avoided to reduce the risk of
central pontine myelinolysis.3
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We read the comment by Tanemoto. with profound
interest. The writer states that hyporeninemic hypoaldos-
teronism may be because of volume expansion in our
case, and that fludrocortisones should not be used
in such a condition. Regarding the issue of volume status,
extra-cellular volume in our patient was not expanded
because edema, body weight gain (changes in body
weight were being monitored in outpatient visits), and
cardiomegaly in chest X-ray were not found. Moreover,
neither the jugular vein nor the vena cava were found
to be dilated in abdominal echography. These findings
together indicated the volume status in our patient was
not expanded in any respect. Rather, she showed
volume depletion, as evidenced by her serum uric acid
level of 7.1 mg/dl. We understand that this is a kind of
chicken and egg problem, but we are sure that she was
volume-depleted without any significant proof of volume
expansion.
The pathophysiology of the hyporeninemic hypo-
aldosteronism in our patient may need more rigorous
investigation, but we attributed it to the direct inhibition
of renin production in juxtaglomerular apparatus by
massive amyloid deposition, as can be seen in Figure 1
of our article.1 Stimulation test of renin secretion by
upright posture and furosemide might have been better
performed. Anyhow, the cause of an undetectable renin
content in our case was ascribed to the problem of the
juxtaglomerular apparatus similar to the condition,
which is associated frequently with diabetes mellitus.
Hyporeninemic hypoaldosteronism is seen mostly in
diabetes mellitus.2
As to how hyporeninemic hypoaldosteronism is treated
in clinical medicine, several measures are postulated,2,3,
and fludrocortisones seemed the reasonable drug of choice
in our case as her volume status was not depleted.
Diuretics were not administered, as she was not edematous
or showed deterioration of renal function probably
because of intravascular volume depletion. In fact,
fludrocortisone has been shown effective in patients
with hyporeninemic hypoaldosteronism.2 We successfully
used fludrocortisone to correct life-threatening hyperkale-
mia without any adverse effect. The result also supported
the idea that she was not volume-expanded, otherwise
the drug might have induced hypervolemic complications
such as peripheral edema, pulmonary edema, pleural
effusion, and even congestive heart failure. Following
fludrocortisone therapy, her serum Na concentration
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decreased from 139 to 137 mmol/l on day 2, and then
increased to 140 mmol/l on day 7. This slow increase in
serum Na concentration did not cause central pontine
myelinolysis.
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About the association between
high alkaline phosphatase
and risk of death and
hospitalization in dialysis
patients
Kidney International (2009) 75, 1114; doi:10.1038/ki.2008.673
To the Editor: We have been very interested by the
epidemiological link between high alkaline phosphatase and
the risk of death and hospitalization in the Dialysis Outcomes
and Practice Patterns Study cohort.1 It is interesting that the
authors pointed out that this association was independent of
calcium, phosphorus, and parathyroid hormone levels, as
well as active vitamin D use. However, no mention was made
about their 25 OH vitamin D serum levels, which may vary
widely according to country latitude, as well as country-
specific reimbursement policy, for intravenous or oral
administration of active or plain vitamin D.
Knowledge of 25 OH vitamin D status is important, as
Wolf et al.2 have pointed out that low 25 OH vitamin D in
incident hemodialysis patients was a strong predictor of early
all-cause mortality.
1. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline
phosphatase levels in hemodialysis patients are associated
with higher risk of hospitalization and death. Kidney Int 2008; 74:
655–663.
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Regarding our article on the Dialysis Outcomes and
Practice Patterns Study (DOPPS),1 the comments by
Baakrim, Shahapuni, Rouached, and Fournier on mortality
risk by serum levels of 25 OH vitamin D2 provide an
important perspective to the dialysis practice. In DOPPS 4,
we inquired about the practice of measuring 25 OH
vitamin D in the sample of international dialysis facilities.
Unfortunately, only 16% of dialysis facility medical
directors indicated that it is being measured routinely
(7% quarterly, 6% biannually, and 3% annually). Any
measurement varied markedly by country, ranging from
0% in the sample of facilities in Australia, New Zealand,
Canada, Sweden, and the United Kingdom to 54% of
facilities in Belgium, 60% in France, and 67% in Germany.
Thus, their comment points to a current area of limited
attention and an opportunity to study the effect of targeted
treatment based on prospective measurement of 25 OH
vitamin D.
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Factors aside from Helicobacter
pylori play an important role in
the occurrence of peptic ulcer
in dialysis patients
Kidney International (2009) 75, 1114–1115; doi:10.1038/ki.2009.26
To the Editor: We read with interest the article entitled
‘Prevalence of Helicobacter pylori in long-term hemodialysis
patients’ by Sugimoto et al.1 In this study, Sugimoto et al.
reported that compared to patients with normal renal
function, the dialysis patients had lower prevalence of
H. pylori, which significantly decreased as the duration of
dialysis increased, and they still had significant peptic ulcer
disease.1 In a 5-year follow-up study of a community
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